Company Filing History:
5 out of 15 
2 out of 1,187 
Years Active: 2020-2025
Title: Lorenz Waldmeier: Innovator in Human Antibodies
Introduction
Lorenz Waldmeier is a prominent inventor based in Basel, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of human antibodies. With a total of five patents to his name, Waldmeier's work focuses on innovative solutions for targeting specific receptors in cancer therapy.
Latest Patents
Waldmeier's latest patents include groundbreaking inventions such as fully human antibodies that bind to the extracellular domain of receptor tyrosine kinase-like orphan receptor 2 (ROR2). This invention aims to enhance therapeutic options for diseases associated with ROR2. Another notable patent involves anti-ROR1 antibodies, which target receptor tyrosine kinase-like orphan receptor-1 (ROR1). This patent encompasses various formats, including bi- or multispecific antibodies and immunoligand-drug conjugates, showcasing Waldmeier's commitment to advancing cancer treatment methodologies.
Career Highlights
Throughout his career, Waldmeier has worked with esteemed organizations such as NBE-Therapeutics AG and The Scripps Research Institute. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to cutting-edge research.
Collaborations
Waldmeier has collaborated with notable colleagues, including Roger Renzo Beerli and Ulf Grawunder. These partnerships have further enriched his research and development efforts in the biotechnology sector.
Conclusion
Lorenz Waldmeier's innovative work in human antibodies positions him as a key figure in the biotechnology industry. His patents reflect a dedication to improving therapeutic strategies for cancer treatment.